JPH06506248A - 新規な非抗凝固剤ヘパリン誘導体 - Google Patents

新規な非抗凝固剤ヘパリン誘導体

Info

Publication number
JPH06506248A
JPH06506248A JP4508854A JP50885492A JPH06506248A JP H06506248 A JPH06506248 A JP H06506248A JP 4508854 A JP4508854 A JP 4508854A JP 50885492 A JP50885492 A JP 50885492A JP H06506248 A JPH06506248 A JP H06506248A
Authority
JP
Japan
Prior art keywords
heparin
periodate
treating
derivative
hydrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4508854A
Other languages
English (en)
Japanese (ja)
Inventor
コンラッド，エイチ．　エドワード
グオ，ユーチュアン
Original Assignee
グライコメッド　インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グライコメッド　インコーポレイテッド filed Critical グライコメッド　インコーポレイテッド
Publication of JPH06506248A publication Critical patent/JPH06506248A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP4508854A 1991-03-29 1992-03-27 新規な非抗凝固剤ヘパリン誘導体 Pending JPH06506248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US677,737 1991-03-29
US07/677,737 US5250519A (en) 1991-03-29 1991-03-29 Non-anticoagulant heparin derivatives
PCT/US1992/002517 WO1992017188A1 (en) 1991-03-29 1992-03-27 New non-anticoagulant heparin derivatives

Publications (1)

Publication Number Publication Date
JPH06506248A true JPH06506248A (ja) 1994-07-14

Family

ID=24719922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4508854A Pending JPH06506248A (ja) 1991-03-29 1992-03-27 新規な非抗凝固剤ヘパリン誘導体

Country Status (7)

Country Link
US (1) US5250519A (Direct)
EP (1) EP0577716A1 (Direct)
JP (1) JPH06506248A (Direct)
AU (1) AU1669592A (Direct)
CA (1) CA2107365A1 (Direct)
NO (1) NO933471L (Direct)
WO (1) WO1992017188A1 (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4754137B2 (ja) * 1999-08-10 2011-08-24 生化学工業株式会社 グリコサミノグリカン誘導体およびその使用

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU5442594A (en) * 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US20020044933A1 (en) * 1993-02-25 2002-04-18 Hart Charles E. Inhibition of intimal hyperplasia using antibodies to PDGF receptors
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5599307A (en) * 1993-07-26 1997-02-04 Loyola University Of Chicago Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
EP2301562B1 (en) * 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5618837A (en) * 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III
CA2248648A1 (en) * 1996-03-15 1997-09-18 Takara Shuzo Co., Ltd. A product of heat treatment of uronic acid, food, drink or drug including the product
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
CA2367288A1 (en) * 1999-04-02 2000-10-12 Netech Inc. Functionalized glycosaminoglycan polymer and medical instruments and drugs by using the same
NZ516229A (en) * 1999-06-30 2004-08-27 Hamilton Civic Hospitals Res Heparin compositions that inhibit clot associated coagulation factors
KR20030069990A (ko) * 2000-09-08 2003-08-27 해밀톤 시빅 호스피탈즈 리서치 디벨로프먼트 인코포레이티드 항혈전 조성물
WO2003059265A2 (en) * 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
AU2003225182B2 (en) * 2002-04-25 2009-02-26 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
CA2540699A1 (en) * 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP4841546B2 (ja) * 2005-03-31 2011-12-21 生化学工業株式会社 新規抗ヘパラン硫酸抗体、ヘパラン硫酸の検出方法、及びヘパラン硫酸検出キット
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
EP2170354A1 (en) * 2007-07-23 2010-04-07 University of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
CN102985443B (zh) 2010-04-16 2017-05-10 动量制药公司 组织靶向
CN103096870B (zh) 2010-06-17 2017-04-19 动量制药公司 调节毛发生长的方法和组合物
DE102011077393A1 (de) 2011-06-10 2012-12-13 Johannes Reinmüller Antiinfektives Mittel
SMT201800143T1 (it) 2011-12-19 2018-05-02 Dilafor Ab Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
SG10201914117QA (en) 2012-05-09 2020-02-27 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression
AU2014274377A1 (en) 2013-05-28 2015-11-12 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
ITLO20130005A1 (it) * 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US20220227855A1 (en) * 2019-04-25 2022-07-21 The University Of Massachusetts Compositions and methods for treatment of angiogenesis related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3422518A1 (de) * 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
DE3519011A1 (de) * 1985-05-25 1986-11-27 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines materials zur affinitaetschromatographie
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4754137B2 (ja) * 1999-08-10 2011-08-24 生化学工業株式会社 グリコサミノグリカン誘導体およびその使用

Also Published As

Publication number Publication date
EP0577716A1 (en) 1994-01-12
NO933471D0 (no) 1993-09-28
EP0577716A4 (Direct) 1994-02-23
CA2107365A1 (en) 1992-09-30
NO933471L (no) 1993-09-28
US5250519A (en) 1993-10-05
AU1669592A (en) 1992-11-02
WO1992017188A1 (en) 1992-10-15

Similar Documents

Publication Publication Date Title
JPH06506248A (ja) 新規な非抗凝固剤ヘパリン誘導体
US5280016A (en) Non-anticoagulant heparin derivatives
AU634199B2 (en) Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
DE68905516T2 (de) Hemmungsmittel des zellwachstums der glatten muskeln.
US5795875A (en) Therapeutic methods of using O-desulfated heparin derivatives
US20190030066A1 (en) Antithrombin-heparin compositions and methods
US3766167A (en) Orally active anticoagulant
JP2001527583A (ja) ヘパリンのｏ−脱硫酸化の制御方法およびそれによって得られる組成物
RU2617764C2 (ru) Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
JPS6227402A (ja) グリコサミノグリカンの硫酸化方法、該方法によつて得られる新規グリコサミノグリカン及びその生物学的適用
JPH02502006A (ja) 抗転移活性を有する硫酸化ポリサッカライド
JP2003512807A (ja) デルマタン二硫酸、トロンビン生成および補体活性化阻害剤
JP6205350B2 (ja) 同じ多糖鎖の４位または６位でバイオテクノロジー的に硫酸化されたコンドロイチン硫酸、およびその調整方法
JPH06506973A (ja) 平滑筋細胞増殖のインヒビターとしての硫酸化多糖類
JPH02108624A (ja) 抗ｈｉｖ作用を有するヘパリンフラグメント及びフラクション
JP2010518251A (ja) ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含むヘパリン、これらの調製方法およびこれらの使用
WO1994008595A1 (en) Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US7618652B2 (en) Glycosaminoglycan anticoagulants derived from fish
WO2002083155A1 (en) Use of sulfated bacterial polysaccharides suitable for the inhibition of angiogenesis
US20060069044A1 (en) Modified glycosaminoglycans, pharmaceutical compositions and methods for oral delivery thereof
US20090275543A1 (en) Modified Glycosaminoglycans, Pharmaceutical Compositions and Methods for Oral Delivery Thereof
EP0351809A2 (en) Blood anticoagulant